Indiana University Health implements new operating model, consolidating regions and eliminating nonclinical leadership roles to improve patient care.

Detailed price information for Design Therapeutics Inc (DSGN-Q) from The Globe and Mail including charting and trades.

I-Mab, a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies ...

The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 ...

The Horizon 3.0 TMS Therapy System is a computerized, noninvasive medical device that directs electrical currents at different regions of the cerebral cortex.

During the conference, Mr. Sapirstein will be available to conduct one-on-one meetings with registered investors, showcasing ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 ...

Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.

Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and ...

Matching grants worth between $10,000 and $50,000 each will support nonclinical, community-based arts programs for U.S. military servicemembers, veterans, and their families and caregivers who have ...

Highmark Health Options, Delaware's largest Medicaid managed care organization announced new coverage options from Highmark Blue Cross Blue Shield that will soon be available. Beginning Jan. 1, 2025, ...

Zucara Therapeutics Inc., ("Zucara" or the "Company") a diabetes life sciences company developing ZT-01, the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people ...